1. Home
  2. OUSTW vs TNFA Comparison

OUSTW vs TNFA Comparison

Compare OUSTW & TNFA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • OUSTW
  • TNFA
  • Stock Information
  • Founded
  • OUSTW N/A
  • TNFA 2014
  • Country
  • OUSTW United States
  • TNFA United States
  • Employees
  • OUSTW N/A
  • TNFA N/A
  • Industry
  • OUSTW Industrial Machinery/Components
  • TNFA
  • Sector
  • OUSTW Industrials
  • TNFA
  • Exchange
  • OUSTW Nasdaq
  • TNFA NYSE
  • Market Cap
  • OUSTW 3.1M
  • TNFA 3.2M
  • IPO Year
  • OUSTW N/A
  • TNFA N/A
  • Fundamental
  • Price
  • OUSTW $0.05
  • TNFA $1.16
  • Analyst Decision
  • OUSTW
  • TNFA
  • Analyst Count
  • OUSTW 0
  • TNFA 0
  • Target Price
  • OUSTW N/A
  • TNFA N/A
  • AVG Volume (30 Days)
  • OUSTW N/A
  • TNFA 297.1K
  • Earning Date
  • OUSTW N/A
  • TNFA 11-14-2024
  • Dividend Yield
  • OUSTW N/A
  • TNFA N/A
  • EPS Growth
  • OUSTW N/A
  • TNFA N/A
  • EPS
  • OUSTW N/A
  • TNFA N/A
  • Revenue
  • OUSTW N/A
  • TNFA N/A
  • Revenue This Year
  • OUSTW N/A
  • TNFA N/A
  • Revenue Next Year
  • OUSTW N/A
  • TNFA N/A
  • P/E Ratio
  • OUSTW N/A
  • TNFA N/A
  • Revenue Growth
  • OUSTW N/A
  • TNFA N/A
  • 52 Week Low
  • OUSTW N/A
  • TNFA $1.05
  • 52 Week High
  • OUSTW N/A
  • TNFA $5.91
  • Technical
  • Relative Strength Index (RSI)
  • OUSTW N/A
  • TNFA 44.65
  • Support Level
  • OUSTW N/A
  • TNFA $1.12
  • Resistance Level
  • OUSTW N/A
  • TNFA $1.52
  • Average True Range (ATR)
  • OUSTW 0.00
  • TNFA 0.12
  • MACD
  • OUSTW 0.00
  • TNFA -0.00
  • Stochastic Oscillator
  • OUSTW 0.00
  • TNFA 12.20

About TNFA TNF PHARMACEUTICALS INC EFFEC

TNF Pharmaceuticals Inc is a clinical-stage pharmaceutical company committed to extending a healthy lifespan. The company is developing and commercializing two therapeutic platforms. MyMD-1 is a small molecule that regulates the immunometabolic system to treat autoimmune diseases, including multiple sclerosis, diabetes, rheumatoid arthritis, and inflammatory bowel disease. It is being developed to treat age-related illnesses such as frailty and sarcopenia. Supera-CBD is a synthetic derivative of CBD being developed to treat various conditions, including epilepsy, pain, and anxiety/depression, through its effects on the CB2 receptor, opioid receptors, and monoamine oxidase enzyme type B.

Share on Social Networks: